Baudax Bio to Participate in the JMP Securities Life Sciences Conference
Baudax Bio (NASDAQ:BXRX) announced that its President and CEO, Gerri Henwood, will participate in a virtual fireside chat at the JMP Securities Life Sciences Conference on June 17, 2021, at 4:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Baudax Bio (NASDAQ:BXRX) announced that its President and CEO, Gerri Henwood, will participate in a virtual fireside chat at the JMP Securities Life Sciences Conference on June 17, 2021, at 4:00 p.m. ET. A live webcast will be available on the company’s investors page, with a replay accessible for 30 days post-event. Baudax Bio focuses on acute care pharmaceutical innovations, including its first product, ANJESO, launched in mid-2020, which is a unique 24-hour intravenous NSAID for managing moderate to severe pain. More details are on the company website.
Details
News Market Reaction – BXRX
The recorded move for BXRX in the trading session of this news was -3.50%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced Gerri Henwood, the Company’s President and Chief Executive Officer, will participate in a fireside chat virtually at the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 4:00 p.m. ET.
A live webcast of the fireside chat will be available on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be available on the Baudax Bio website for a period of 30 days following the event.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings. The launch of Baudax Bio’s first commercial product ANJESO® began in mid-2020. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies. For more information, please visit www.baudaxbio.com.
CONTACT:
Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com
Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.